Current stage-Stage III Posts on Medivizor
Navigation Menu

Current stage-Stage III Posts on Medivizor

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Read More

Evaluating the effectiveness and safety of robotic versus laparoscopic resections for patients with low rectal cancer.

Evaluating the effectiveness and safety of robotic versus laparoscopic resections for patients with low rectal cancer.

Posted by on Feb 27, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of robotic versus laparoscopic abdominoperineal resections (APRs) for the treatment of patients with low rectal cancer (RC). The data showed that robotic APRs significantly reduced surgical trauma and promoted recovery after surgery compared with laparoscopic APRs in these patients. Some...

Read More

Evaluating the long-term effectiveness and safety of 3-month versus 6-month modified FOLFOX/CAPOX treatment after surgery in patients with stage 3 colon cancer.

Evaluating the long-term effectiveness and safety of 3-month versus 6-month modified FOLFOX/CAPOX treatment after surgery in patients with stage 3 colon cancer.

Posted by on Oct 13, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of 3-month versus 6-month modified FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) treatment after surgery in patients with stage 3 colon cancer. The data showed that 3-month modified FOLFOX/CAPOX treatment was as effective and safe as...

Read More

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Posted by on Jun 30, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC).  This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...

Read More

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Posted by on May 8, 2022 in Breast cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...

Read More

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Investigating the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma.

Posted by on May 8, 2022 in Melanoma | 0 comments

In a nutshell This study investigated the benefit of frequent surveillance imaging on the survival outcomes in patients with resected stage III melanoma. The data showed that patients who underwent less frequent imaging (12-monthly) had better outcomes than those who underwent more frequent imaging (3- to 4-monthly). Some background Melanoma is a...

Read More

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Posted by on Mar 20, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk factors associated with acute radiation dermatitis (ARD; skin irritation) after radiotherapy (RT) in patients with breast cancer (BC). The data showed that patients with diabetes, smokers, and those with a body mass index (BMI; a measure of body weight in relation to height) of more than 25 kg/m2 had a...

Read More

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Posted by on Jan 30, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...

Read More

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Posted by on Dec 31, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small-cell lung cancer (NSCLC). The data showed that immunotherapies plus chemotherapy combination was the best treatment for improving overall survival whereas, immunotherapy plus anti-angiogenic therapy plus chemotherapy...

Read More

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Posted by on Dec 31, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in...

Read More

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Evaluating the effectiveness and safety outcomes of durvalumab maintenance after chemoradiotherapy for unresectable stage 3 non-small-cell lung cancer.

Posted by on Nov 28, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of durvalumab (Imfinzi) maintenance after chemoradiotherapy (CRT) in real-world patients with unresectable stage 3 non-small-cell lung cancer (NSCLC). The data showed that durvalumab maintenance after CRT was safe and showed good short-term survival outcomes in these...

Read More

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Evaluating the effectiveness of T-VEC after failure of immunotherapy in patients with unresectable metastatic melanoma.

Posted by on Nov 27, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness of talimogene laherparepvec (Imlygic; T-VEC) after failure of immunotherapy for the treatment of patients with unresectable metastatic melanoma. The data showed that T-VEC after the failure of immunotherapy is safe and effective in these patients. Some background Melanoma is an aggressive type of...

Read More